Ann: U.S. Remote Therapeutic Monitoring Codes Finalised, page-8

I wonder how much longer before we get more information on the progress about these snippets below from the last quarterly, or are they just going to inform us at the next quarterly in a few weeks. . I Know the asx has cracked down on what is and isn't deemed market sensitive or non market sensitive announcements but personally I would like to see more news flow from the company.

Work on manufacturing readiness for market release before the end of the calendar year of the new sensor for AstraZeneca’s Symbicort® pMDI which this quarter received the U.S. Food and Drug Administration (FDA) 510(k)clearance to market as the first, next generation Hailie® Sensor with physiological measures

;o Build out of the ecosystem through adding digitalised third-party respiratory devices and information which will increase relevant data available to treating physicians with the first third-party device expected to be integrated before calendar year end

;o Building physiological measures into the new GSK, Ellipta and Pro air sensors with 510(k) submissions during 2021 and 2022;o Extending Adherium’s ecosystem integration layer through the release of our SDK and 2nd generation interface REST API before calendar year end.

I would like to think that 2022 should be ADR's breakout year, especially in the US.